García-Gila M, Cabañas C, García-Pardo A
Departamento de Inmunología, Centro di Investigaciones Biológicas, CSIC, Madrid, Spain.
FEBS Lett. 1997 Dec 1;418(3):337-40. doi: 10.1016/s0014-5793(97)01407-5.
Myeloma cells specifically localize in the bone marrow and rarely circulate in blood. To study whether this immobilization could be partially explained by the presence of constitutively activated integrins, particularly alpha4beta1, we used the activation reporter HUTS-21 anti-beta1 mAb. These analyses showed that beta1 integrins on myeloma cells were moderately active and could be upregulated similarly to integrins on lymphoma or leukemia cells. Myeloma cells were also tested for their ability to attach to RGD-containing fibronectin fragments, a property of activated (but not resting) alpha4beta1. Two cell lines adhered to these fragments and this was inhibited by anti-alpha5 but not by anti-alpha4 mAbs. These results show that myeloma cells bear low/moderately active alpha4beta1 and support the notion that multiple interactions contribute to their localization in the bone marrow.
骨髓瘤细胞特异性定位于骨髓,很少在血液中循环。为了研究这种固定化是否可以部分归因于组成性激活的整合素(特别是α4β1)的存在,我们使用了激活报告物HUTS-21抗β1单克隆抗体。这些分析表明,骨髓瘤细胞上的β1整合素具有中等活性,并且可以与淋巴瘤或白血病细胞上的整合素类似地上调。还测试了骨髓瘤细胞附着于含RGD的纤连蛋白片段的能力,这是激活的(而非静止的)α4β1的特性。两种细胞系附着于这些片段,并且这种附着被抗α5单克隆抗体抑制,但不被抗α4单克隆抗体抑制。这些结果表明,骨髓瘤细胞带有低/中等活性的α4β1,并支持多种相互作用有助于其在骨髓中定位的观点。